Targeting this CAF phenotype is therefore an attractive therapeutic option, and in this study, we show that NOX4 is a common regulator of myofibroblast accumulation in many human cancers that can be targeted pharmacologically to suppress/revert myofibroblastic CAF differentiation and slow tumor growth. The gene discussed is NOX4; the disease is neoplasm.